Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin
- PMID: 40044251
- DOI: 10.1016/S2352-3026(25)00030-4
Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin
Conflict of interest statement
DPdW is doing a PhD programme partially funded by Momenta Pharmaceuticals, which was acquired by Johnson & Johnson, and was an investigator for a phase 2 trial (NCT03842189) and is an investigator for a phase 3 trial (NCT05912517) of a new drug for the treatment of HDFN. EJTV was the principal investigator for a phase 2 trial (NCT03842189) and is the principal investigator for a phase 3 trial (NCT05912517) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. EL was a sub-investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. All other authors declare no competing interests. DPdW and JMMvK accessed and verified the data in this study. The study was funded by Sanquin Blood Supply. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Comment on
-
Predicting anaemia and transfusion dependency in severe alloimmune haemolytic disease of the fetus and newborn in the first 3 months after birth.Br J Haematol. 2019 Aug;186(4):565-573. doi: 10.1111/bjh.15962. Epub 2019 May 29. Br J Haematol. 2019. PMID: 31140599
References
Publication types
LinkOut - more resources
Full Text Sources